|Cat. No. HS-454 008||
100 µl purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.', $event)" style="cursor: help;">ICC: 1 : 1000 gallery
Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.', $event)" style="cursor: help;">IHC-P: 1 : 200 up to 1 : 1000 gallery
|Subtype||IgG1 (κ light chain)|
|Immunogen||Synthetic peptide corresponding to residues surrounding AA 450 of human CK7 (UniProt Id: P08729)|
Reacts with: human (P08729).
No signal: mouse (Q9DCV7).
Other species not tested yet.
This antibody is a chimeric antibody based on the monoclonal rat antibody clone 123E11H11. The constant regions of the heavy and light chains have been replaced by rabbit specific sequences. Therefore, the antibody can be used with standard anti-rabbit secondary reagents. The antibody has been expressed in mammalian cells.
Cytokeratin 7 staining in human invasive breast cancer
Cytokeratins are cytoskeleton proteins of epithelial tissues, contributing to the mechanical stabilization of the cells. The cytokeratin family consists of at least 20 isotypes, which are largely specific for particular organs or tissue types. Therefore, immunohistochemical staining of cytokeratins is clinically used for diagnosis of carcinomas, in particular of unclear metastases and in precise classification and subtyping of tumors (1). Cytokeratin 7 (CK7) is expressed in healthy bladder, in the female genital tract epithelium, in mesothelium and in the lung (2). In tumors, CK7 expression is found in the majority of carcinoma types, with the exception of those carcinomas arising from the colon, prostate, kidney and thymus (3). Furthermore, CK7 expression can have prognostic relevance, e.g. adverse prognostic factor in lung cancer (4), or predictive relevance, e.g. predictive factor of response to concurrent radiochemotherapy in advanced cervical cancer (5).